J Korean Assoc Oral Maxillofac Surg.  2025 Jan;51(1):17-25. 10.5125/jkaoms.2025.51.1.17.

Prognostic factors influencing implant survival and marginal bone loss in patients with osteoporosis or osteopenia medication

• Lee SA
• Yi YJ
• Won S
• Chang NH
• Kim JH

• KMID: 2565634
• DOI: http://doi.org/10.5125/jkaoms.2025.51.1.17

Abstract

Objectives
To evaluate the factors that influence the survival of dental implants and marginal bone loss (MBL) in patients taking osteoporosis or osteopenia medication.
Materials and Methods
This study included patients who underwent dental implant treatment after taking medication for osteoporosis or osteopenia. Electronic medical records were used to collect data of patient age, sex, age at osteoporosis or osteopenia diagnosis, types of medications, age at medication initiation, duration of medication before implant surgery, whether the medication was paused before surgery, paused duration of medication, implant survival status, and MBL before and after prosthetic treatment. Firth’s logistic regression was used to analyze the relationships between each variable and implant survival as well as between MBL before and after prosthetic treatment.
Results
Of the 267 patients, 111 with 209 implants were included in the study. The mean observation period was 57.9 months. The survival rate was 92.8% at the patient level and 96.2% at the implant level. No significant associations were found between implant survival and any of the variables examined. MBL before prosthetic treatment was significantly associated with use of receptor activator of nuclear factor-κB ligand (RANKL) inhibitors (P=0.032) and bone formation stimulators (P=0.022). Comparing the concurrent and single use of bisphosphonates and RANKL inhibitors, only the use of RANKL inhibitors alone was significantly associated with MBL before prosthetic treatment (P=0.039). MBL after prosthetic treatment was significantly associated with injection method among the routes of drug administration (P=0.011).
Conclusion
The implant survival rate in patients undergoing medical treatment for osteoporosis or osteopenia was comparable to the general implant survival rate. MBL before prosthetic treatment was associated with type of anti-osteoporotic medication, whereas MBL after prosthetic treatment was correlated with drug administration route. Further studies with larger sample sizes are required.

Keyword

Osteoporosis; Osteopenia; Dental implants; Marginal bone loss; Survival rate

Reference

References

1. Buser D, Sennerby L, De Bruyn H. 2017; Modern implant dentistry based on osseointegration: 50 years of progress, current trends and open questions. Periodontol 2000. 73:7–21. https://doi.org/10.1111/prd.12185. DOI: 10.1111/prd.12185. PMID: 28000280.

2. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B. 2012; Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet. 380:37–43. https://doi.org/10.1016/s0140-6736(12)60240-2. DOI: 10.1016/S0140-6736(12)60240-2. PMID: 22579043.

3. Lane JM, Russell L, Khan SN. 2000; Osteoporosis. Clin Orthop Relat Res. 372:139–50. https://doi.org/10.1097/00003086-200003000-00016. DOI: 10.1097/00003086-200003000-00016. PMID: 10738423.

4. Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, et al. 2021; The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 16:609. https://doi.org/10.1186/s13018-021-02772-0. DOI: 10.1186/s13018-021-02772-0. PMID: 34657598. PMCID: PMC8522202.

5. Sarafrazi N, Wambogo EA, Shepherd JA. 2021; Osteoporosis or low bone mass in older adults: United States, 2017-2018. NCHS Data Brief. 405:1–8. https://doi.org/10.15620/cdc:103477. DOI: 10.15620/cdc:103477.

6. Grassi S, Piattelli A, Ferrari DS, Figueiredo LC, Feres M, Iezzi G, et al. 2007; Histologic evaluation of human bone integration on machined and sandblasted acid-etched titanium surfaces in type IV bone. J Oral Implantol. 33:8–12. https://doi.org/10.1563/0-791.1. DOI: 10.1563/0-791.1. PMID: 17410906.

7. Shibli JA, Grassi S, de Figueiredo LC, Feres M, Marcantonio E Jr, Iezzi G, et al. 2007; Influence of implant surface topography on early osseointegration: a histological study in human jaws. J Biomed Mater Res B Appl Biomater. 80:377–85. https://doi.org/10.1002/jbm.b.30608. DOI: 10.1002/jbm.b.30608. PMID: 16850464.

8. Raisz LG. 2005; Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 115:3318–25. https://doi.org/10.1172/jci27071. DOI: 10.1172/JCI27071. PMID: 16322775. PMCID: PMC1297264.

9. Geurs NC. 2007; Osteoporosis and periodontal disease. Periodontol 2000. 44:29–43. https://doi.org/10.1111/j.1600-0757.2006.00194.x. DOI: 10.1111/j.1600-0757.2006.00194.x. PMID: 17474924.

10. Pan J, Shirota T, Ohno K, Michi K. 2000; Effect of ovariectomy on bone remodeling adjacent to hydroxyapatite-coated implants in the tibia of mature rats. J Oral Maxillofac Surg. 58:877–82. https://doi.org/10.1053/joms.2000.8212. DOI: 10.1053/joms.2000.8212. PMID: 10935587.

11. Hildebolt CF. 1997; Osteoporosis and oral bone loss. Dentomaxillofac Radiol. 26:3–15. https://doi.org/10.1038/sj.dmfr.4600226. DOI: 10.1038/sj.dmfr.4600226. PMID: 9446984.

12. Jeffcoat MK, Lewis CE, Reddy MS, Wang CY, Redford M. 2000; Post-menopausal bone loss and its relationship to oral bone loss. Periodontol 2000. 23:94–102. https://doi.org/10.1034/j.1600-0757.2000.2230109.x. DOI: 10.1034/j.1600-0757.2000.2230109.x. PMID: 11276771.

13. Southard KA, Southard TE, Schlechte JA, Meis PA. 2000; The relationship between the density of the alveolar processes and that of post-cranial bone. J Dent Res. 79:964–9. https://doi.org/10.1177/00220345000790041201. DOI: 10.1177/00220345000790041201. PMID: 10831099.

14. Kribbs PJ, Chesnut CH 3rd, Ott SM, Kilcoyne RF. 1989; Relationships between mandibular and skeletal bone in an osteoporotic population. J Prosthet Dent. 62:703–7. https://doi.org/10.1016/0022-3913(89)90596-9. DOI: 10.1016/0022-3913(89)90596-9. PMID: 2585328.

15. Mombelli A, Cionca N. 2006; Systemic diseases affecting osseointegration therapy. Clin Oral Implants Res. 17 Suppl 2:97–103. https://doi.org/10.1111/j.1600-0501.2006.01354.x. DOI: 10.1111/j.1600-0501.2006.01354.x. PMID: 16968386.

16. Temmerman A, Rasmusson L, Kübler A, Thor A, Merheb J, Quirynen M. 2019; A prospective, controlled, multicenter study to evaluate the clinical outcome of implant treatment in women with osteoporosis/osteopenia: 5-year results. J Dent Res. 98:84–90. https://doi.org/10.1177/0022034518798804. DOI: 10.1177/0022034518798804. PMID: 30205020.

17. Aljohani S, Fliefel R, Ihbe J, Kühnisch J, Ehrenfeld M, Otto S. 2017; What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a systematic review. J Craniomaxillofac Surg. 45:1493–502. https://doi.org/10.1016/j.jcms.2017.05.028. DOI: 10.1016/j.jcms.2017.05.028. PMID: 28687467.

18. Karimi D, Arduino PG, Gambino A, Erovigni F, Dell'Acqua A, Pera F, et al. 2024; A multi-center observation study on medication-related osteonecrosis of the jaw (MRONJ) in patients with osteoporosis, and other non-malignant bone diseases, in Northwestern Italy over 16 years. Biomedicines. 12:2179. https://doi.org/10.3390/biomedicines12102179. DOI: 10.3390/biomedicines12102179. PMID: 39457492. PMCID: PMC11505559.

19. World Health Organization (WHO) Scientific Group on the Prevention and Management of Osteoporosis. 2003. Prevention and management of osteoporosis: report of a WHO scientific group. WHO.

20. Buser D, Mericske-Stern R, Bernard JP, Behneke A, Behneke N, Hirt HP, et al. 1997; Long-term evaluation of non-submerged ITI implants. Part 1: 8-year life table analysis of a prospective multi-center study with 2359 implants. Clin Oral Implants Res. 8:161–72. https://doi.org/10.1034/j.1600-0501.1997.080302.x. DOI: 10.1034/j.1600-0501.1997.080302.x. PMID: 9586460.

21. Cochran DL, Buser D, ten Bruggenkate CM, Weingart D, Taylor TM, Bernard JP, et al. 2002; The use of reduced healing times on ITI implants with a sandblasted and acid-etched (SLA) surface: early results from clinical trials on ITI SLA implants. Clin Oral Implants Res. 13:144–53. https://doi.org/10.1034/j.1600-0501.2002.130204.x. DOI: 10.1034/j.1600-0501.2002.130204.x. PMID: 11952734.

22. Holahan CM, Koka S, Kennel KA, Weaver AL, Assad DA, Regennitter FJ, et al. 2008; Effect of osteoporotic status on the survival of titanium dental implants. Int J Oral Maxillofac Implants. 23:905–10.

23. Lee G, Um YJ, Jung UW, Kim CS, Choi SH, Cho KS, et al. 2009; A retrospective study of survival rate of dental implants placed in osteoporosis patients. J Korean Acad Periodontol. 39:413–23. https://doi.org/10.5051/jkape.2009.39.4.413. DOI: 10.5051/jkape.2009.39.4.413.

24. Howe MS, Keys W, Richards D. 2019; Long-term (10-year) dental implant survival: a systematic review and sensitivity meta-analysis. J Dent. 84:9–21. https://doi.org/10.1016/j.jdent.2019.03.008. DOI: 10.1016/j.jdent.2019.03.008. PMID: 30904559.

25. Ting M, Huynh BH, Woldu HG, Gamal I, Suzuki JB. 2023; Clinical impact on dental implant survival in patients taking antiresorptive medications: a systematic review and meta-analysis. J Oral Implantol. 49:599–615. https://doi.org/10.1563/aaid-joi-d-21-00160. DOI: 10.1563/aaid-joi-D-21-00160. PMID: 37905745.

26. Kim B, Kim M. 2021; Bone health and L-ascorbic acid in postmenopausal women. J Life Sci. 31:1142–8. https://doi.org/10.5352/JLS.2021.31.12.1142. DOI: 10.1038/s41422-021-00568-9. PMID: 34526662. PMCID: PMC8441950.

27. Zhang YY, Xie N, Sun XD, Nice EC, Liou YC, Huang C, et al. 2024; Insights and implications of sexual dimorphism in osteoporosis. Bone Res. 12:8. https://doi.org/10.1038/s41413-023-00306-4. DOI: 10.1038/s41413-023-00306-4. PMID: 38368422. PMCID: PMC10874461.

28. de-Freitas NR, Lima LB, Veloso-Guedes CC, Simamoto-Júnior PC. 2016; Bisphosphonate treatment and dental implants: a systematic review. Med Oral Patol Oral Cir Bucal. 21:e644–51. https://doi.org/10.4317/medoral.20920. DOI: 10.4317/medoral.20920. PMID: 27475681. PMCID: PMC5005105.

29. Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Schiødt M, Klinge B. 2018; The effect of antiresorptive drugs on implant therapy: systematic review and meta-analysis. Clin Oral Implants Res. 29 Suppl 18:54–92. DOI: 10.1111/clr.13282. PMID: 30306695.

30. Drake MT, Clarke BL, Khosla S. 2008; Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 83:1032–45. https://doi.org/10.4065/83.9.1032. DOI: 10.4065/83.9.1032. PMID: 18775204. PMCID: PMC2667901.

31. Patel HK, Bihani T. 2018; Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol Ther. 186:1–24. https://doi.org/10.1016/j.pharmthera.2017.12.012. DOI: 10.1016/j.pharmthera.2017.12.012. PMID: 29289555.

32. Hanley DA, Adachi JD, Bell A, Brown V. 2012; Denosumab: mechanism of action and clinical outcomes. Int J Clin Pract. 66:1139–46. https://doi.org/10.1111/ijcp.12022. DOI: 10.1111/ijcp.12022. PMID: 22967310. PMCID: PMC3549483.

33. Quattrocchi E, Kourlas H. 2004; Teriparatide: a review. Clin Ther. 26:841–54. https://doi.org/10.1016/s0149-2918(04)90128-2. DOI: 10.1016/S0149-2918(04)90128-2. PMID: 15262455.

34. Haynes DR, Crotti TN, Potter AE, Loric M, Atkins GJ, Howie DW, et al. 2001; The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J Bone Joint Surg Br. 83:902–11. https://doi.org/10.1302/0301-620x.83b6.10905. DOI: 10.1302/0301-620X.83B6.10905. PMID: 11521937.

35. Baron R, Ferrari S, Russell RG. 2011; Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 48:677–92. https://doi.org/10.1016/j.bone.2010.11.020. DOI: 10.1016/j.bone.2010.11.020. PMID: 21145999.

36. Diz P, López-Cedrún JL, Arenaz J, Scully C. 2012; Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc. 143:981–4. https://doi.org/10.14219/jada.archive.2012.0323. DOI: 10.14219/jada.archive.2012.0323. PMID: 22942143.

37. Taylor KH, Middlefell LS, Mizen KD. 2010; Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg. 48:221–3. https://doi.org/10.1016/j.bjoms.2009.08.030. DOI: 10.1016/j.bjoms.2009.08.030. PMID: 19836866.

38. Kakehashi H, Ando T, Minamizato T, Nakatani Y, Kawasaki T, Ikeda H, et al. 2015; Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings. Int J Oral Maxillofac Surg. 44:1558–64. https://doi.org/10.1016/j.ijom.2015.07.018. DOI: 10.1016/j.ijom.2015.07.018. PMID: 26304604.

39. Kim JY, Park JH, Jung HD, Jung YS. 2019; Treatment of medication-related osteonecrosis of the jaw around the dental implant with a once-weekly teriparatide: a case report and literature review. J Oral Implantol. 45:403–7. https://doi.org/10.1563/aaid-joi-d-19-00040. DOI: 10.1563/aaid-joi-D-19-00040. PMID: 31429640.

40. Devlin H, Greenwall-Cohen J, Benton J, Goodwin TL, Littlewood A, Horner K. 2018; Detecting the earliest radiological signs of bisphosphonate-related osteonecrosis. Br Dent J. 224:26–31. https://doi.org/10.1038/sj.bdj.2017.1001. DOI: 10.1038/sj.bdj.2017.1001. PMID: 29192692.

41. Lemos CAA, de Oliveira AS, Faé DS, Oliveira HFFE, Del Rei Daltro Rosa CD, Bento VAA, et al. 2023; Do dental implants placed in patients with osteoporosis have higher risks of failure and marginal bone loss compared to those in healthy patients? A systematic review with meta-analysis. Clin Oral Investig. 27:2483–93. https://doi.org/10.1007/s00784-023-05005-2. DOI: 10.1007/s00784-023-05005-2. PMID: 37043030.

42. Puhr R, Heinze G, Nold M, Lusa L, Geroldinger A. 2017; Firth's logistic regression with rare events: accurate effect estimates and predictions? Stat Med. 36:2302–17. https://doi.org/10.1002/sim.7273. DOI: 10.1002/sim.7273. PMID: 28295456.

43. Firth D. 1993; Bias reduction of maximum likelihood estimates. Biometrika. 80:27–38. https://doi.org/10.1093/biomet/80.1.27. DOI: 10.1093/biomet/80.1.27.

44. de Medeiros FCFL, Kudo GAH, Leme BG, Saraiva PP, Verri FR, Honório HM, et al. 2018; Dental implants in patients with osteoporosis: a systematic review with meta-analysis. Int J Oral Maxillofac Surg. 47:480–91. https://doi.org/10.1016/j.ijom.2017.05.021. DOI: 10.1016/j.ijom.2017.05.021. PMID: 28651805.

45. Erdoğan O, Shafer DM, Taxel P, Freilich MA. 2007; A review of the association between osteoporosis and alveolar ridge augmentation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 104:738.e1–13. https://doi.org/10.1016/j.tripleo.2007.04.008. DOI: 10.1016/j.tripleo.2007.04.008. PMID: 17656117.

46. Diz P, Scully C, Sanz M. 2013; Dental implants in the medically compromised patient. J Dent. 41:195–206. https://doi.org/10.1016/j.jdent.2012.12.008. DOI: 10.1016/j.jdent.2012.12.008. PMID: 23313715.